Business News • PR NewsWire • BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO

BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO

BerGenBio - Invitation to Conference Call: Interim Update on Ph II Clinical Programme With Selective AXL Inhibitor Bemcentinib Being Presented at ASCO

BERGEN, Norway, May 29, 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) will host a conference call on Monday, 4 June at 8:30 AM CEST to present updated interim clinical and biomarker results from its ongoing Phase II development programme with selective AXL inhibitor bemcentinib. The data...

View More : https://www.prnewswire.com/news-releases/bergenbio---invitation-to-conference-call-interim-update-on-ph-ii-clinical-prog...

Releted News by prnewswire

Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder

Sectra's Year-end Report 2017/2018: Positive Earnings Trend and Healthy Order Book

GLOSFER Recruits Former CTO of Cisco, Monique Morrow